Dividend.com: Will Lilly Blossom?
Molex Cuts Outlook on Lower Demand
Molex (MOLX), manufacturer and seller of electronic components worldwide, cut its first-quarter outlook -- citing lower demand in its telecom, data infrastructure and automotive markets.
Management says the industrial and consumer electronic markets are below the company's original outlook -- as customers remain cautious in their procurement and forecasting -- given the significant uncertainty in the global economy.
For the first quarter, Molex sees earnings of 25 cents to 29 cents a share -- below Reuters consensus estimates of 38 cents a share.We have avoided the shares since our early June coverage began, when Molex shares were trading in the $27-$28 range. We recommend looking elsewhere for better investment opportunities. The company has a 2.75% dividend yield, based on last night's closing stock price of $22.19. Molex is not a recommended dividend stock at this time, holding a Dividend.com Rating of 3.2 out of 5 stars.
Eli Lilly Reportedly Offering $70 per Share for ImClone According to various news reports, Eli Lilly (LLY) is in advanced talks to acquire ImClone Systems (IMCL) for $70 per share in cash in a $6.1 billion deal. Eli Lilly's offer significantly trumps the latest offer from Bristol Myers (BMY) of $62 per share. Bristol Myers already owns a 17% stake in ImClone Systems. Eli Lilly is looking to add to its current slate of Oncology products -- which presently include Alimta and Gemzar. ImClone's cancer treatment Erbitux -- which is used to combat colorectal, head and neck, and lung cancers -- had sales of about $1.3 billion in 2007.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV